HIV / AIDS in the News

The EXPrESSIVE trials test a monthly pill for PrEP: Advocates speak - European AIDS Treatment Group

 

Gilead Sciences' Yeytuo: A Paradigm Shift in HIV Prevention and a Catalyst for Long-Term Profitability - AInvest

 

Mental disorders linked to shorter life expectancy in people with HIV - European AIDS Treatment Group

 

CATIE: TreatmentUpdate 255: US funding cuts, HIV prevention, anti-HIV agents, inflammation - European AIDS Treatment Group

 

Addressing excess visceral abdominal fat and cardiometabolic risk in people with HIV - European AIDS Treatment Group

 

How HIV Uses T Cells to Hide in the Gut | Newswise - Newswise

 

European Commission authorizes twice-yearly Yeytuo® (lenacapavir) for HIV prevention - European AIDS Treatment Group

 

Structural brain differences in school-aged children who are HIV-exposed uninfected - BMC Medicine

 

European Union Approves Gilead Sciences’ Long-Acting HIV Prevention Injection Yeytuo - geneonline.com

 

GILD Wins Approval for Twice-Yearly HIV Prevention Shot in the EU - TradingView

 

GILD Wins Approval for Twice-Yearly HIV Prevention Shot in the EU - Yahoo Finance

 

Gilead Granted Marketing Authorization for Twice-Yearly HIV PrEP Shot in Europe - Contract Pharma

 

GILD Wins Approval for Twice-Yearly HIV Prevention Shot in the EU - Zacks Investment Research

 

EU approves new twice-yearly jab to prevent HIV - Euronews.com

 

WCC publishes “HIV, Migration, and Forced Displacement: What Can the Churches Do?” - World Council of Churches

 

Are We Getting Closer To A Broader Cure For HIV? - Forbes

 

Gilead’s Yeytuo approved in EU, boosting its blockbuster potential - Pharmaceutical Technology

 

US aid cuts: South Africa trans health worker describes HIV fear - Context News

 

Gilead poised to bring twice-yearly HIV PrEP to EU - pharmaphorum

 

Gilead twice-yearly HIV PrEP drug OKed in EU (GILD:NASDAQ) - Seeking Alpha

 

Gilead Sciences' Yeztugo: A Paradigm Shift in HIV Prevention and Investment Potential - AInvest

 

Gilead wins European approval for HIV prevention injection - Investing.com

 

Health advocates fight back: Legal battle over US foreign aid cuts - capetimes.co.za

 

Distribution of CCR5-Δ32 and HLA-B*57:01 alleles in HIV-seropositive and HIV-exposed seronegative Peruvian individuals | Human Genome Variation - Nature

 

European Commission Authorizes Twice-Yearly Yeytuo® (Lenacapavir) for HIV Prevention - Yahoo Finance

 

EU approves Gilead's new injection for preventing HIV - Reuters

 

Gilead Sciences' 99.9% Effective HIV Treatment Notches Another Win - Investor's Business Daily

 

European Commission Authorizes Twice-Yearly Yeytuo® (Lenacapavir) for HIV Prevention - Business Wire

 

‘I was imprisoned for six months for being HIV-positive’ - The Independent

 

‘I was imprisoned for six months for being HIV-positive’ - the-independent.com